Novavax Reports First Quarter 2024 Financial Results and Operational Highlights
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...
Novavax reports mixed Q1 results; narrows FY24 revenue outlook below estimates
Q1 GAAP EPS of -$1.05 beats by $0.01. Revenue of $94M (+16.0% Y/Y) misses by $7.45M. Cash, cash equivalents and restricted cash were $496 million as of March 3 ...
Novavax Inc. Q1 Loss Decreases, Beats Estimates
Novavax Inc. (NVAX) released Loss for first quarter that decreased from last year and beat the Street estimates. The company's ...
Investing11m
Novavax stock soars 40% on Sanofi partnership
Novavax (NASDAQ: NVAX ) shares rocketed 40% in premarket trading Friday, driven by the company’s fiscal Q1 2024 report and more importantly, a vital, multi-billion dollar deal with French pharma giant ...
Seeking Alpha2d
Novavax top investor calls for removal of three company directors
International investment firm Shah Capital, a top shareholder of Novavax (NASDAQ:NVAX), has called on the company's ...
Novavax investor pushes for changes in proxy fight
A Novavax shareholder thinks leadership has failed to capitalize on its business opportunity — so the investor is pushing to change that.
CORRECTED-Novavax erases doubts about its ability to remain in business
COVID-19 vaccine maker Novavax , on Friday, erased doubts about its ability to remain in business by removing a so-called "going concern" notice. In February last year, Novavax had raised doubts about ...
Novavax's top shareholder Shah Capital ramps up efforts for board shakeup
Hedge fund Shah Capital on Monday urged Novavax shareholders to vote against the re-election of three directors and proposals ...